Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 9 clinical trials
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma

This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory renal cell carcinoma.

carcinoma
renal cell carcinoma
karnofsky performance status
  • 0 views
  • 19 Feb, 2024
Lenvatinib and Pembrolizumab Before Surgery for the Treatment of Locally Advanced Non-Metastatic Kidney Cancer

This phase II trial studies how well lenvatinib and pembrolizumab before surgery work in treating patients with kidney cancer that has spread from its original site of growth to nearby tissues or lymph nodes but has not spread to other places in the body (non-metastatic).

monoclonal antibodies
liver metastasis
kidney cancer
conjugated bilirubin
azoospermia
  • 8 views
  • 19 Feb, 2024
  • 1 location
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Localized Renal Tumor

This may help doctors and patients with renal tumors in the future to make better treatment decisions.

aggressiveness
hyperpolarized carbon c 13 pyruvate
estimated creatinine clearance
nephrectomy
cancer
  • 0 views
  • 19 Feb, 2024
Dose Escalation of DF6002 in Patients With Advanced Solid Tumors and Expansion in Selected Indications

This study is a Phase 1/2, open-label, dose-escalation study with a consecutive parallel-group efficacy expansion study, designed to determine the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of DF6002 as monotherapy and in combination with pembrolizumab.

advanced renal cell carcinoma
growth factor
carcinoma
renal pelvis
BRAF
  • 0 views
  • 19 Feb, 2024
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of administering T cell products derived from the research participant's blood that have been genetically modified to express a …

iobenguane
tumors in children
cetuximab
biotherapy
steroid therapy
  • 0 views
  • 19 Feb, 2024
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.

monoclonal antibodies
myelosuppressive chemotherapy
immunohistochemistry
biologics
growth factor
  • 0 views
  • 19 Feb, 2024
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

radiopharmaceutical
bone marrow procedure
pleural effusion
growth factor
tipifarnib
  • 0 views
  • 19 Feb, 2024
Evaluation of Clinical Radiomics and Molecular Features of Lung Metastasis in PDAC Patients (LUMACA Trial)

The aim of this study is the characterization from epidemiological, radiomics and molecular point of view of lung metastasis of patients at beginning affected by pancreatic adenocarcinoma (PDAC), which after the resection of primitive tumor have met with initial recurrence of the disease exclusively at the lung level.

pdac
metastasis
primary tumor
adenocarcinoma
pancreatic adenocarcinoma
  • 0 views
  • 19 Feb, 2024
Therapeutic Recommendations for Nephroblastoma

The study is based on results form 2 previous studies carried out by the GFAOP. The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.

wilms' tumour / nephroblastoma
  • 0 views
  • 19 Feb, 2024